Navigation Links
FDA Approves New Drug for Severe Epilepsy

Trials showed Banzel proved effective against Lennox-Gastaut syndrome

FRIDAY, Nov. 21 (HealthDay News) -- A new drug called Banzel (rufinamide) has been approved as a supplementary treatment for a severe form of epilepsy called Lennox-Gastaut syndrome, the U.S. Food and Drug Administration announced Friday.

The approval was based on results of a four-month clinical trial that included patients ages 4 to 30. Compared to patients who took a placebo, those who took the drug had 41 percent fewer tonic plus atonic seizures and 20 percent fewer seizures of any type, the agency said in a news release.

Common side effects included headache, dizziness, fatigue, drowsiness, double vision, nausea, vomiting, and problems walking.

As with all other antiepileptic drugs, Banzel will carry a warning that it may increase the risk of suicidal thoughts or behaviors. All patients who take Banzel must be given a patient medication guide that describes the risk of suicidal thoughts and behaviors associated with this class of drugs, the FDA said.

Banzel, manufactured by Eisai Medical Research Inc. of Woodcliff Lake, N.J., was granted "orphan drug status" by the FDA. This designation is given to a drug intended to treat a disease or condition that affects fewer than 200,000 people in the United States.

Lennox-Gastaut syndrome usually begins before age 4 and can be caused by brain malformations, severe head injury, central nervous system infection and inherited degenerative or metabolic conditions. No cause can be found in 30 percent to 35 percent of cases, the FDA said.

Patients with this form of epilepsy may experience periods of frequent seizures mixed with brief, relatively seizure-free periods. They suffer from varying types of seizures, including tonic (stiffening of the body, upward deviation of the eyes, dilation of the pupils, and altered respiratory patterns), atonic (brief loss of muscle tone and consciousness, causing abrupt falls), atypical absence (staring spells), and myoclonic (sudden muscle jerks).

Most children with Lennox-Gastaut syndrome have some degree of impaired intellectual functioning or information processing, as well as developmental delays and behavioral issues.

"This approval offers another treatment option for patients who suffer from these debilitating, severe seizures," Dr. Russell Katz, director of the division of neurology products in the FDA's Center for Drug Evaluation and Research, said in the news release.

More information

Epilepsy Ontario has more about Lennox-Gastaut syndrome.

-- Robert Preidt

SOURCE: U.S. Food and Drug Administration news release, Nov. 21, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause
2. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse
3. Pennsylvania Insurance Department Approves Launch of Senior Health Care Oversight Trust
4. US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients During Early Morning Period
5. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection
6. Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million
7. Kaiser Permanente Approves $12 Million in Community Benefit Grants in Third Quarter of 2008
8. Congress Sets New Course for Lung Cancer Research; Approves $20 Million for New Defense Department Program
9. FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old
10. ClearWay Minnesota(SM) Board Approves New Officers
11. FDA approves first drug for Huntingtons disease
Post Your Comments:
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: